Literature DB >> 8605354

Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1.

S Takeuchi1, C R Bartram, C W Miller, A Reiter, T Seriu, M Zimmerann, M Schrappe, N Mori, J Slater, I Miyoshi, H P Koeffler.   

Abstract

Cytogenetic analysis of acute lymphoblastic leukemia (ALL) of childhood identified nonrandom chromosomal abnormalities of the short arm of chromosome 12. The alterations include deletions that are thought to be indicative of the presence of a tumor suppressor gene that is mutated on the remaining allele. To refine further the chromosomal localization of this gene, we analyzed the loss of heterozygosity (LOH) of chromosome 12 in 100 primary ALL samples using 22 polymorphic markers and identified two distinct smallest common deleted regions on chromosome 12p13. One region is flanked by D12S77 and D12S98 and has a size of 4 cM. Twenty-six percent of informative patients showed LOH in this region. This region may contain the TEL gene. The other region is flanked by D12S269 and D12S308 including the KIP1 gene. Forty-four percent of informative patients showed LOH in this second region. Mutational analysis of KIP1 using polymerase chain reaction-single-strand conformation polymorphism analysis and Southern blot analysis showed no homozygous deletions and point mutations suggesting that the altered gene in this second region is not the KIP1. Clinical data showed that LOH of 12p was demonstrated more frequently in precursor-B ALLs (32 of 80; 40%) than in T-ALLs (1 of 20; 5%) (P = .0027). Furthermore, patients with 12p LOH were younger (P = .013), with a lower DNA index (P = .046), but they had the same survival rates at 3 years. In summary, these data suggest that two different tumor suppressor genes are on chromosome arm 12p, which act separately in the development of childhood precursor-B ALLs. One of the tumor suppressor genes is in the region the KIP1 gene, but our data suggest this gene is not abnormal. The other target is in the region of the TEL gene; and this candidate deserves further study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605354

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array.

Authors:  Sarina Sulong
Journal:  Malays J Med Sci       Date:  2010-07

2.  Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL.

Authors:  L C Wang; F Kuo; Y Fujiwara; D G Gilliland; T R Golub; S H Orkin
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

3.  CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.

Authors:  Claudia Haferlach; Ulrike Bacher; Alexander Kohlmann; Sonja Schindela; Tamara Alpermann; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach
Journal:  Haematologica       Date:  2011-03-21       Impact factor: 9.941

4.  TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1.

Authors:  R Fenrick; L Wang; J Nip; J M Amann; R J Rooney; J Walker-Daniels; H C Crawford; D L Hulboy; M S Kinch; L M Matrisian; S W Hiebert
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer.

Authors:  Suwon Kim; Koei Chin; Joe W Gray; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-04       Impact factor: 11.205

6.  LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Christoph Plass; Carl Morrison; Yian Wang; Jonathan S Wiest; Marshall W Anderson; Ming You
Journal:  Oncogene       Date:  2003-02-27       Impact factor: 9.867

Review 7.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

8.  Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.

Authors:  Y Hatta; S Takeuchi; J Yokota; H P Koeffler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Fluorescence in situ hybridization analysis of 12;21 translocation in Japanese childhood acute lymphoblastic leukemia.

Authors:  M Eguchi-Ishimae; M Eguchi; K Tanaka; K Hamamoto; M Ohki; K Ueda; N Kamada
Journal:  Jpn J Cancer Res       Date:  1998-07

10.  Analysis of the conservation of synteny between Fugu and human chromosome 12.

Authors:  Alexandre Montpetit; Michael D Wilson; Mario Chevrette; Ben F Koop; Daniel Sinnett
Journal:  BMC Genomics       Date:  2003-07-23       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.